Abcellera Biologics Inc Asset Turnover Ratio (ABCL), as of first quarter 2026, current and historic results, rankings and more - CSIMarket
CSIMarket
 


Abcellera Biologics Inc   (NASDAQ: ABCL)
 

Abcellera Biologics Inc Asset Turnover Ratio

Quarterly Results, Trends, Rankings, Statistics

Abcellera Biologics Inc 's asset turnover ratio has remained unchanged compare to previous quarter at 0.06 in the first quarter (Mar 31 2026)

Within sector 170 more businesses have achieved higher asset turnover ratio. While Asset turnover ratio total ranking has improved so far during the I Quarter 2026, to 3299, from total ranking in the fourth quarter 2025 at 3873.

Asset Turnover Ratio Definition



ABCL Asset Turnover Ratio (Mar 31 2026)
I. Quarter
(Dec 31 2025)
IV. Quarter
(Sep 30 2025)
III. Quarter
(Jun 30 2025)
II. Quarter
(Mar 31 2025)
I. Quarter
Y / Y Asset Change -3.63 % 12.59 % 6.96 % 10.77 % 0.13 %
Y / Y Revenue Change 96.34 % 788.37 % 37.62 % 133.29 % -57.45 %
Asset Turnover Ratio (TTM) 0.06 0.06 0.03 0.03 0.02
ABCL's Total Ranking # 3299 # 3873 # 3845 # 3919 # 4010
Seq. Asset Change -4.54 % 0.07 % -3.29 % 4.3 % 11.53 %
Seq. Revenue Change -81.46 % 400.88 % -47.58 % 303.4 % -16.12 %



Asset Turnover Ratio Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 171
Healthcare Sector # 499
Overall Market # 3299

Asset Turnover Ratio Statistics
High Average Low
0.4 0.13 0.02
(Sep 30 2022)   (Mar 31 2025)







Companies with similar Asset Turnover Ratio for the quarter ending Mar 31 2026, within Healthcare Sector Asset Turnover Ratio Revenues for 12 Months ending Mar 31 2026 Assets at quarter ending Mar 31 2026
Prothena Corporation Public Limited Company  0.16 $ 57.940  Millions$ 357.098  Millions
Maxcyte inc   0.16 $ 32.287  Millions$ 207.552  Millions
Skinvisible Inc   0.15 $ 0.020  Millions$ 0.131  Millions
China Pharma Holdings Inc  0.15 $ 3.992  Millions$ 26.429  Millions
Autolus Therapeutics Plc  0.15 $ 92.624  Millions$ 624.765  Millions
Standard Biotools Inc   0.15 $ 85.215  Millions$ 575.867  Millions
Lineage Cell Therapeutics Inc   0.15 $ 14.779  Millions$ 100.639  Millions
Nektar Therapeutics  0.14 $ 55.633  Millions$ 388.140  Millions
Femasys Inc   0.14 $ 2.377  Millions$ 16.823  Millions
Safe Pro Group Inc   0.13 $ 1.642  Millions$ 12.272  Millions
Scilex Holding Company  0.13 $ 33.862  Millions$ 254.563  Millions
Foghorn Therapeutics Inc   0.13 $ 28.224  Millions$ 212.867  Millions
Septerna Inc   0.13 $ 72.255  Millions$ 546.940  Millions
Ispecimen inc   0.13 $ 1.027  Millions$ 7.793  Millions
Petvivo Holdings Inc   0.13 $ 0.821  Millions$ 6.266  Millions
Igc Pharma Inc   0.13 $ 1.166  Millions$ 8.905  Millions
Renovorx Inc   0.13 $ 1.489  Millions$ 11.727  Millions
Coherus Oncology inc   0.13 $ 46.883  Millions$ 370.087  Millions
Royalty Pharma Plc  0.13 $ 2,440.522  Millions$ 19,276.619  Millions
Bioadaptives Inc   0.13 $ 0.024  Millions$ 0.190  Millions
Ginkgo Bioworks Holdings Inc   0.12 $ 141.311  Millions$ 1,143.236  Millions
Lucid Diagnostics Inc   0.12 $ 5.134  Millions$ 41.598  Millions
Nurix Therapeutics Inc   0.12 $ 71.779  Millions$ 609.573  Millions
Seastar Medical Holding Corp  0.12 $ 1.436  Millions$ 12.334  Millions
Xencor Inc  0.12 $ 97.360  Millions$ 840.144  Millions
Beam Therapeutics Inc   0.12 $ 164.011  Millions$ 1,416.053  Millions
Arvinas Inc   0.11 $ 89.400  Millions$ 779.750  Millions
C4 Therapeutics Inc   0.11 $ 34.861  Millions$ 312.488  Millions
Sintx Technologies Inc   0.11 $ 1.029  Millions$ 9.469  Millions
Protagonist Therapeutics inc   0.11 $ 74.063  Millions$ 696.335  Millions



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.